ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Kawasumi Laboratories, Inc.

  • 629.00 JPY
  • -4.00
  • -0.63%
  • Japan
    Dec 17, 2018
  • Ticker
    TKS(7703)
  • Prev. close
    633
  • Market cap (JPY)
    14,526.08M
  • Market cap (USD)
    128.07M
  • Shares
    22.94M

Business Summary

Kawasumi Laboratories, Inc. engages in the manufacture and sale of medical devices and pharmaceuticals. It operates through the Hemodialysis and Plasmapheresis and Blood Transfusion and Endovascular segments. The Hemodialysis and Plasmapheresis segment develops, produces, and sells dialyzers, blood tubing lines, AV Fistula needles, and isotonic sodium chloride solutions. It also offers removal of pathogenic factors from blood by extracorporeal circulation. The Blood Transfusion and Endovascular segment sells dialyzers, blood circuits, AVF needles, filters for blood purification and artificial heart-lung circuits. The company was founded by Takumi Kawano on December 1, 1954 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue25,437M229.50M
Gross Profit8,683M78.34M
Operating income688M6.20M
Income before tax733M6.61M
Net income440M3.96M
EBITDA2,377M21.44M
Diluted EPS20.160.18
Dividends Per Share150.13
Total Assets45,539M428.19M
Total liabilities6,080M57.16M
Total equity39,020M366.90M
Operating cash flow2,760M24.90M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 27,625M 28,408M 28,135M 24,726M 25,437M
Gross Profit 8,650M 9,530M 10,129M 8,861M 8,683M
Operating income 248M 1,407M 2,130M 924M 688M
Income before tax 1,085M 1,749M 2,160M 1,017M 733M
Net income 606M 975M 1,167M 1,116M 440M
EBITDA 2,945M 3,515M 3,963M 2,544M 2,377M
Diluted EPS 26.53 42.63 51.46 51.16 20.16
Dividends Per Share 15 15 15 17.50 15
Total Assets 42,613M 45,704M 43,868M 43,848M 45,539M
Total liabilities 7,083M 6,815M 6,851M 5,690M 6,080M
Total equity 35,199M 38,481M 36,626M 37,752M 39,020M
Operating cash flow 4,572M 5,059M 3,225M 2,947M 2,760M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 275.77M 258.59M 234.29M 228.33M 229.50M
Gross Profit 86.35M 86.74M 84.34M 81.82M 78.34M
Operating income 2.47M 12.80M 17.73M 8.53M 6.20M
Income before tax 10.83M 15.92M 17.98M 9.39M 6.61M
Net income 6.04M 8.87M 9.71M 10.30M 3.96M
EBITDA 29.39M 31.99M 33.00M 23.49M 21.44M
Diluted EPS 0.26 0.38 0.42 0.47 0.18
Dividends Per Share 0.14 0.13 0.12 0.16 0.13
Total Assets 413.77M 381.10M 390.30M 393.50M 428.19M
Total liabilities 68.77M 56.82M 60.95M 51.06M 57.16M
Total equity 341.78M 320.87M 325.86M 338.79M 366.90M
Operating cash flow 45.64M 46.05M 26.85M 27.21M 24.90M

Valuation Measures

Mar 2018
PER43.03
ROA0.98%
ROE1.14%
Operating margin2.70%
Profit margin1.72%

Key executives

  • President & Representative Director: Yoshio Sakaya
  • Director, Managing Executive Officer, Head-R&D: Noriaki Shirahama
  • Executive Officer & Manager-Accounting: Koichi Ukegawa
  • Director & Managing Executive Officer: Takeshi Yuasa
  • Director, Head-Personnel & System: Takeshi Saino

Shareholders

  • Kawasumi Laboratories, Inc. (10.1%)
  • Kuraray Co., Ltd. (9.4%)
  • Asahi Kasei Corp. (8.7%)
  • Olympus Corp. (4.3%)
  • Mitsui Chemicals Pension Fund (3.1%)
  • Sumitomo Mitsui Financial Group, Inc. (3.1%)
  • Moriroku Holdings Co., Ltd. (2.6%)
  • Dimensional Fund Advisors LP (2.3%)
  • The Iyo Bank, Ltd. (2.1%)
  • Oita Bank, Ltd. (2.1%)

Contact Details

  • Website:http://www.kawasumi.jp
  • Address: Shinagawa Intercity Tower B, 9/F, 2-15-2 Konan, Tokyo, 108-6109, Japan
  • Phone: +81.3.5769.2600

Related Companies

  • Namsin Trading Co. Ltd.
  • Kawasumi Platech, Inc.
  • Kawasumi Laboratories Thailand Co. Ltd.
  • Kawasumi Laboratories America, Inc.

Competitors

  • Fresenius Medical Care AG & Co. KGaA
  • Bioteque Corporation
Last Updated on 17 Dec, 2018

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

{{sentenceStarter}} {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media